Grail CEO Jennifer Cook has stepped down from the cancer diagnostics developer and its board of directors.
Menlo Park, CA-based Grail said Thursday that Cook left due to “family health reasons.” Hans Bishop, a Grail director since last August, was appointed Cook’s successor in the chief executive role. He will also remain on Grail’s board. Bishop is the founder and former president and CEO of Juno Therapeutics, which was acquired by Celgene (NASDAQ: CELG) last year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,